Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-Potassium (HP) blood cardioplegia is a specialized cardioplegic solution used during open-heart surgery to induce and maintain cardiac arrest. In the context of clinical research at Xijing Hospital, "HP" refers to a cold blood-based solution containing potassium chloride at a concentration of 20 mmol/L. The high concentration of potassium ions (K⁺) works by depolarizing the cardiac myocyte membrane, which inactivates voltage-gated sodium channels and prevents the generation of action potentials, thereby arresting the heart in diastole. This reduces myocardial oxygen demand and provides a still, bloodless field for surgical procedures, such as the repair of congenital heart defects in pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on high-potassium blood cardioplegia.